Stefan Fröhling
Stefan Fröhling
National Center for Tumor Diseases, German Cancer Research Center, Heidelberg
Bestätigte E-Mail-Adresse bei nct-heidelberg.de - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine, M Wadleigh, J Cools, BL Ebert, G Wernig, BJP Huntly, ...
Cancer cell 7 (4), 387-397, 2005
31002005
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
RF Schlenk, K Döhner, J Krauter, S Fröhling, A Corbacioglu, L Bullinger, ...
New England Journal of Medicine 358 (18), 1909-1918, 2008
17392008
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
DA Barbie, P Tamayo, JS Boehm, SY Kim, SE Moody, IF Dunn, ...
Nature 462 (7269), 108-112, 2009
12852009
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia
L Bullinger, K Döhner, E Bair, S Fröhling, RF Schlenk, R Tibshirani, ...
New England Journal of Medicine 350 (16), 1605-1616, 2004
10852004
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene …
K Döhner, RF Schlenk, M Habdank, C Scholl, FG Rücker, ...
Blood 106 (12), 3740-3746, 2005
9112005
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML …
S Fröhling, RF Schlenk, J Breitruck, A Benner, S Kreitmeier, K Tobis, ...
Blood, The Journal of the American Society of Hematology 100 (13), 4372-4380, 2002
8862002
Activating mutations in ALK provide a therapeutic target in neuroblastoma
RE George, T Sanda, M Hanna, S Fröhling, W Luther II, J Zhang, Y Ahn, ...
Nature 455 (7215), 975-978, 2008
7902008
CEBPA Mutations in Younger Adults With Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating Mutations
S Fröhling, RF Schlenk, I Stolze, J Bihlmayr, A Benner, S Kreitmeier, ...
Journal of Clinical Oncology 22 (4), 624-633, 2004
5482004
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells
C Scholl, S Fröhling, IF Dunn, AC Schinzel, DA Barbie, SY Kim, SJ Silver, ...
Cell 137 (5), 821-834, 2009
5452009
Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in …
F Edelmann, G Gelbrich, HD Düngen, S Fröhling, R Wachter, ...
Journal of the American College of Cardiology 58 (17), 1780-1791, 2011
5052011
Genetics of myeloid malignancies: pathogenetic and clinical implications
S Fröhling, C Scholl, DG Gilliland, RL Levine
Journal of Clinical Oncology 23 (26), 6285-6295, 2005
4372005
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
FG Rücker, RF Schlenk, L Bullinger, S Kayser, V Teleanu, H Kett, ...
Blood, The Journal of the American Society of Hematology 119 (9), 2114-2121, 2012
3982012
Prognostic Significance of Partial Tandem Duplications of the MLL Gene in Adult Patients 16 to 60 Years Old With Acute Myeloid Leukemia and Normal …
K Döhner, K Tobis, R Ulrich, S Fröhling, A Benner, RF Schlenk, ...
Journal of Clinical Oncology 20 (15), 3254-3261, 2002
3622002
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B
S Fröhling, RF Schlenk, S Kayser, M Morhardt, A Benner, K Döhner, ...
Blood 108 (10), 3280-3288, 2006
3012006
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia
MG Kharas, CJ Lengner, F Al-Shahrour, L Bullinger, B Ball, S Zaidi, ...
Nature medicine 16 (8), 903, 2010
2882010
Chromosomal abnormalities in cancer
S Fröhling, H Döhner
New England Journal of Medicine 359 (7), 722-734, 2008
2542008
AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias
SM Sykes, SW Lane, L Bullinger, D Kalaitzidis, R Yusuf, B Saez, F Ferraro, ...
Cell 146 (5), 697-708, 2011
2222011
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B
RF Schlenk, K Döhner, M Kneba, K Götze, F Hartmann, F Del Valle, ...
haematologica 94 (1), 54-60, 2009
2022009
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
S Fröhling, C Scholl, RL Levine, M Loriaux, TJ Boggon, OA Bernard, ...
Cancer cell 12 (6), 501-513, 2007
1802007
FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia
BH Lee, Z Tothova, RL Levine, K Anderson, N Buza-Vidas, DE Cullen, ...
Cancer cell 12 (4), 367-380, 2007
1762007
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20